Overview
Ayaka Katayama practices practicing medicine in Maebashi, Japan.
Ms. Katayama is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, and Fibroadenoma.
She is actively involved in clinical research, co-authoring 38 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Ayaka Katayama
Is Ayaka Katayama a top-rated expert for Breast Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Ayaka Katayama is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Ayaka Katayama participate in research or clinical trials?
Yes. Ayaka Katayama has published 38 articles and abstracts on conditions like Breast Cancer. You can view a list of Ayaka Katayama's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Breast CancerMs. Katayama isAdvanced. Learn about Breast Cancer.
- Experienced
- FibroadenomaMs. Katayama isExperienced. Learn about Fibroadenoma.
- Triple-Negative Breast CancerMs. Katayama isExperienced. Learn about Triple-Negative Breast Cancer.